Evidence-based decision support for primary care — Kenneth Tan Medical Clinic
Select a condition
Answer clinical questions step by step
See your path through the decision tree
Get evidence-based recommendations
Go back anytime to explore different scenarios
Select a clinical condition to begin your interactive care pathway
Evidence-based approach to blood pressure assessment and pharmacological management in primary care.
ACE Clinical Guidance (Singapore, Dec 2023)
Risk stratification and lipid-lowering therapy selection based on cardiovascular risk profile.
ACE Clinical Guidance — Lipid Management (Dec 2023)
Antiplatelet therapy, DAPT after PCI, AF management with OAC, comorbidity optimisation, anti-anginal selection, and lifestyle.
ACE Clinical Guidance (Singapore, Mar 2025)
Stroke risk assessment (modified CHA₂DS₂-VASc), DOAC vs warfarin selection, renal-based dosing, bleeding risk, INR management, and switching protocols.
ACE Clinical Guidance (Singapore, Nov 2023)
DOAC/warfarin selection for DVT and PE, dosing by patient population (general, cancer, renal impairment, pregnancy), treatment duration, and switching protocols.
ACE Clinical Guidance (Singapore, May 2024)
Lifestyle intervention, metformin consideration, and monitoring to prevent or delay progression to type 2 diabetes.
ACE Appropriate Care Guide (Singapore, Jul 2021)
Comprehensive approach to diabetes screening, diagnosis, treatment intensification, and basal insulin initiation.
ACE Clinical Guidance (Singapore, 2023–2024)
Screening, diagnosis and follow-up of GDM across pregnancy trimesters and postpartum, including IADPSG diagnostic criteria.
ACE Appropriate Care Guide (Singapore, Aug 2022)
Active foot condition triage, DFU risk stratification (callus, deformity, PAD, neuropathy), referral guidance, and patient education on foot care and footwear.
ACE Clinical Guidance (Singapore, Aug 2024)
Acute flare treatment, urate-lowering therapy initiation, SCAR monitoring, prophylaxis, and long-term management.
ACE Clinical Guidance (Singapore, Dec 2023)
Risk identification, DXA interpretation, bisphosphonate and denosumab selection, monitoring, drug holidays, and specialist referral.
ACE Clinical Guidance (Singapore, Aug 2025)
Diagnostic pathway from presenting symptoms through spirometry, bronchodilator reversibility, and PEF variability to confirmation or alternative diagnosis workup.
GINA 2025 Summary Guide
Track 1 (ICS-formoterol) and Track 2 (SABA) treatment options across GINA Steps 1–4 with specific medication and dosing guidance. Step 5 refers to specialist.
GINA 2025 Summary Guide
Paediatric stepwise treatment from low-dose ICS through ICS-LABA and MART, with age-appropriate dosing and specialist referral criteria.
GINA 2025 Summary Guide
Primary care management of acute asthma — severity assessment, bronchodilator and corticosteroid treatment, response monitoring, discharge criteria, and follow-up.
GINA 2025 Summary Guide
Spirometry-based diagnosis, stepwise inhaler pharmacotherapy (LAMA → LAMA+LABA → triple therapy), eosinophil-guided ICS, smoking cessation, and inhaler technique.
ACE Clinical Guidance (Singapore, Dec 2024)
Structured diagnostic pathway: risk factors, spirometry (FEV₁/FVC <0.7), GOLD grade 1–4, mMRC/CAAT symptom scoring, and ABE group classification replacing the old ABCD model.
GOLD 2026 Pocket Guide
Initial treatment by ABE group, eosinophil-guided ICS decisions (≥300, 100–299, <100), follow-up treatment for persistent dyspnoea vs exacerbations, triple therapy, roflumilast/azithromycin add-ons, and non-pharmacological essentials.
GOLD 2026 Pocket Guide
Rome criteria severity classification (mild/moderate/severe), acute SABA and prednisolone dosing, antibiotic selection with specific regimens, hospital referral red flags, and post-exacerbation follow-up within 1–4 weeks.
GOLD 2026 Pocket Guide
Diagnostic approach to upper respiratory tract infections and acute cough in primary care.
MOH Antibiotic Stewardship Guidelines
Uncomplicated cystitis and pyelonephritis diagnosis, urine dipstick interpretation, empirical antibiotics (nitrofurantoin, amoxicillin-clavulanate, fosfomycin), and referral criteria.
ACE Clinical Guidance (Singapore, Dec 2023)
Guidance on appropriate CXR ordering — general medical examinations, preoperative testing, and lung cancer screening.
ACE Clinical Guidance (Singapore, May 2021)
CT and MRI ordering guidance for primary and secondary headaches, using the SNNOOP10 red flag framework.
ACE Clinical Guidance (Singapore, Aug 2022)
Appropriate use of lumbar spine MRI — non-specific vs specific pathology, red flags, cauda equina, and post-procedural pain.
ACE Clinical Guidance (Singapore, Oct 2020)
Severity assessment (GAD-7), CBT and SSRI/SNRI selection by severity, suboptimal response management, remission maintenance, and benzodiazepine guidance.
ACE Clinical Guidance (Singapore, Mar 2025)
Severity assessment (PHQ-9), psychological vs pharmacological treatment by severity, antidepressant selection, suboptimal response management, and relapse prevention.
ACE Clinical Guidance (Singapore, Mar 2025)